+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Recombinant Hormone Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4987062
  • Report
  • February 2020
  • Region: Global
  • 120 pages
  • Mordor Intelligence
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Eli Lilly and Company
  • Ferring Pharmaceuticals
  • Ipsen Pharma
  • LG Life Sciences
  • Merck & Co Inc
  • Novo Nordisk A/S
  • MORE
The Recombinant Hormone Market is expected to register a CAGR of 6.4% during the forecast period. The recombinant hormone is the hormone made in a laboratory using recombinant technology which is used for therapeutic purposes. The endocrine system in the human body consists of glands (pituitary gland, thyroid gland, parathyroid glands, adrenal glands, pancreas, etc.) that produce hormones and regulate different functions such as metabolism, growth and development, reproduction, sexual function, tissue function, mood, and sleep, among other functions. If hormone levels are too high or too low indicate a problem with the endocrine system. In the human body, peptide hormones are secreted after encoding by peptide hormone genes in the specialized cells, such as insulin and another human growth hormone.

The most common endocrine disease in the United States is diabetes, a condition in which the body does not produce glucose, and this is due to the lack of insulin or it may be the body that is not working effectively with produced insulin. Some of the common endocrine disorders are Type 1 and Type 2 Diabetes, Osteoporosis, Thyroid Cancer, Addison’s Disease, etc.

According to International Diabetes Federation, approximately 463 million adults were living with diabetes in the year 2019 and by the year 2045 this will rise to 700 million worldwide and 79% of adults with diabetes are from low- and middle-income countries.

Technological advancements in the development of recombinant hormone therapies, hormonal disorders with rising geriatric population are the key driving factors in the recombinant hormone market.

Key Market Trends

Insulin Segment is Expected to Hold a Major Market Share in the Recombinant Hormone Market
  • The insulin hormone is secreted by the beta cells of Islets of Langerhans of the pancreas which catabolizes glucose in the blood. Insulin helps to keep blood sugar level from getting too high (hyperglycemia) or too low (hypoglycemia).
  • According to the International Diabetes Federation, globally, about 374 million people are at increased risk of developing type 2 diabetes and more than 1.1 million children and adolescents are living with type 1 diabetes. In addition, deaths due to diabetes were about 4.2 million in the year 2019.
  • Approximately 100 million people around the world are in need of insulin, including people with Type 1 diabetes and Type 2 diabetes. In addition, insulin has been used in the treatment of diabetes for over 90 years, globally, more than half of those who need insulin today still cannot afford and access it.
  • Rising incidence of diabetes and technological advancements in recombinant insulin hormones are the key driving factors in the insulin segment.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the global recombinant hormone market due to increasing incidence of hormonal disorders. Moreover, companies investing in research and development for developing a growth hormone that has fewer side effects and will be long-acting hormonal in this region.

According to Centers for Disease Control and Prevention, more than 30 million Americans have diabetes and 84 million United States adults have prediabetes. In addition, in the year 2017, the total estimated cost of diagnosed diabetes was about 327 billion dollars, including 237 billion in medical costs and 90 billion in reduced productivity. Furthermore, technological advancements in recombinant hormonal therapies, increasing healthcare spending and presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.

Competitive Landscape

The Recombinant Hormone Market is consolidated competitive and consists of few major players. In terms of market share, few of the major players are currently dominating the market. Collaborations and mergers over the next coming years to share technology and increasing investments for innovation in the field are expected to be observed. Some of the companies which control significant market share include Eli Lilly and Company, Ferring Pharmaceuticals, Hoffmann La Roche Ltd (Genentech, Inc), Merck & Co Inc, Pfizer Inc, Novo Nordisk A/S, Novartis AG (Sandoz International GmbH), Ipsen Pharma, LG Life Sciences and Teva Pharmaceutical Industries.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • Report customization as per the client's requirements.
  • 3 months of analyst support.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Eli Lilly and Company
  • Ferring Pharmaceuticals
  • Ipsen Pharma
  • LG Life Sciences
  • Merck & Co Inc
  • Novo Nordisk A/S
  • MORE
1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence of Growth Disorders and Diabetes
4.2.2 Technological Advancements in Development of Recombinant Hormonal Therapies
4.3 Market Restraints
4.3.1 Adverse Effects Associated with Recombinant Hormonal Therapies
4.3.2 Stringent Regulatory Processes
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

5.1 By Product Type
5.1.1 Growth Hormone
5.1.2 Insulin
5.1.3 Follicle-stimulating Hormone
5.1.4 Other Products
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle-East and Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle-East and Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles
6.1.1 Eli Lilly and Company
6.1.2 Ferring Pharmaceuticals
6.1.3 F.Hoffmann-La Roche Ltd (Genentech
6.1.4 Merck & Co Inc
6.1.5 Pfizer Inc
6.1.6 Novo Nordisk A/S
6.1.7 Novartis AG (Sandoz International GmbH)
6.1.8 Ipsen Pharma
6.1.9 LG Life Sciences
6.1.10 Teva Pharmaceutical Industries

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Eli Lilly and Company
  • Ferring Pharmaceuticals
  • F.Hoffmann-La Roche Ltd (Genentech
  • Merck & Co Inc
  • Pfizer Inc
  • Novo Nordisk A/S
  • Novartis AG (Sandoz International GmbH)
  • Ipsen Pharma
  • LG Life Sciences
  • Teva Pharmaceutical Industries
Note: Product cover images may vary from those shown
Adroll
adroll